A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

Background: Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare, indolent subtype of non-Hodgkin lymphoma ...

Title: The Evolution of Anti-CD20 Treatment for Multiple Sclerosis ... The discussion of these refinements includes improving the extent of B-cell depletion, reducing infusion-related reactions ...